These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29197360)

  • 1. Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations.
    Axcrona K; Nilsson R; Brennhovd B; Sørebø Ø; Fosså SD; Dahl AA
    BMC Urol; 2017 Dec; 17(1):111. PubMed ID: 29197360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer.
    Lam WWT; Tse MA; Ng CNL; Chung EKM; Fielding R
    J Pain Symptom Manage; 2017 Jun; 53(6):1085-1090. PubMed ID: 28438583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometric testing of the Norwegian version of the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26).
    Fosså SD; Storås AH; Steinsvik EA; Myklebust TA; Eri LM; Loge JH; Dahl AA
    Scand J Urol; 2016 Aug; 50(4):280-5. PubMed ID: 27049891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments.
    Protopapa E; van der Meulen J; Moore CM; Smith SC
    BJU Int; 2017 Oct; 120(4):468-481. PubMed ID: 28437031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the Italian version of the abbreviated expanded prostate Cancer index composite (EPIC-26) in men with prostate Cancer.
    Marzorati C; Monzani D; Mazzocco K; Masiero M; Pavan F; Monturano M; Pravettoni G
    Health Qual Life Outcomes; 2019 Aug; 17(1):147. PubMed ID: 31464649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Portuguese version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): psychometric validation and prospective application for early functional outcomes at a single institution.
    Lourenço DB; Amaral BS; Alfer-Junior W; Vasconcellos A; Russo F; Sanchez-Salas R; Bianco B; Wagner AA; Chang P; Moschovas MC; Lemos GC; Carneiro A
    BMC Urol; 2020 Oct; 20(1):163. PubMed ID: 33081748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain.
    Zapatero A; Maldonado Pijoan X; Gómez-Caamaño A; Pardo Masferrer J; Macías Hernández V; Hervás Morón A; Muñoz García JL; Palacios Eito A; Anguita-Alonso P; González-Junco C; López Torrecilla J
    Health Qual Life Outcomes; 2021 Sep; 19(1):223. PubMed ID: 34563208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments.
    Vertosick EA; Vickers AJ; Cowan JE; Broering JM; Carroll PR; Cooperberg MR
    J Urol; 2017 Sep; 198(3):671-677. PubMed ID: 28342935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
    Wei JT; Dunn RL; Litwin MS; Sandler HM; Sanda MG
    Urology; 2000 Dec; 56(6):899-905. PubMed ID: 11113727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric validation of the Spanish version of the Expanded Prostate Cancer Index Composite-26.
    Zamora V; Garin O; Suárez JF; Jové J; Castells M; Ferrer F; Gutiérrez C; Guedea F; Boladeras A; Fumadó L; Roselló A; Pastor J; Samper P; Pont À; Ferrer M
    World J Urol; 2023 Dec; 41(12):3511-3518. PubMed ID: 37947846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes.
    Willis DL; Gonzalgo ML; Brotzman M; Feng Z; Trock B; Su LM
    BJU Int; 2012 Mar; 109(6):898-905. PubMed ID: 21933328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer.
    Sibert NT; Dieng S; Oesterle A; Feick G; Carl G; Steiner T; Minner J; Roghmann F; Kaftan B; Zengerling F; Hinkel A; Beyer B; Heidenreich A; Harke N; Brehmer B; Pfitzenmaier J; Fichtner J; Neisius A; Hammerer P; Wesselmann S; Kowalski C
    World J Urol; 2021 Jan; 39(1):11-25. PubMed ID: 31552467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life after radical treatment of prostate cancer: validation of the Italian version of the University of California-Los Angeles Prostate Cancer Index.
    Gacci M; Livi L; Paiar F; Detti B; Litwin MS; Bartoletti R; Giubilei G; Cai T; Mariani M; Carini M
    Urology; 2005 Aug; 66(2):338-43. PubMed ID: 16098363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.
    Litwin MS; Hays RD; Fink A; Ganz PA; Leake B; Brook RH
    Med Care; 1998 Jul; 36(7):1002-12. PubMed ID: 9674618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the measurement properties of the 26-item Expanded Prostate Cancer Index Composite (EPIC-26) with a multicenter cohort.
    Crump RT; Peterson A; Charbonneau C; Carlson KV; Sutherland JM; Baverstock RJ
    Can Urol Assoc J; 2020 Apr; 14(4):111-117. PubMed ID: 31702548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the Brazilian version of the Expanded Prostate Cancer Index Composite (EPIC) for patients submitted to radical prostatectomy.
    Alves E; Medina R; Andreoni C
    Int Braz J Urol; 2013; 39(3):344-52. PubMed ID: 23849583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: an evaluation of health related quality of life in Japanese men with localized prostate cancer.
    Namiki S; Takegami M; Kakehi Y; Suzukamo Y; Fukuhara S; Arai Y
    J Urol; 2007 Aug; 178(2):473-7; discussion 477. PubMed ID: 17561164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation.
    Umbehr MH; Bachmann LM; Poyet C; Hammerer P; Steurer J; Puhan MA; Frei A
    Health Qual Life Outcomes; 2018 Feb; 16(1):36. PubMed ID: 29458434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Creation and Psychometric Validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in Sexual Minority Patients-The Restore-2 Study.
    Polter EJ; Kohli N; Rosser BRS; Talley KMC; Wheldon CW; Hoefer CJ; Wright M; Haggart R; Mitteldorf D; Kilian G; Konety BR; Ross MW; West W
    J Sex Med; 2022 Mar; 19(3):529-540. PubMed ID: 35131199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
    Szymanski KM; Wei JT; Dunn RL; Sanda MG
    Urology; 2010 Nov; 76(5):1245-50. PubMed ID: 20350762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.